Werewolf Therapeutics Updates Pipeline and Outlines 2026 Priorities

The latest update is out from Werewolf Therapeutics ( (HOWL) ).

On December 18, 2025, Werewolf Therapeutics reported a pipeline update and 2026 business priorities centered on its INDUKINE and INDUCER platforms, highlighting preliminary clinical data and a shift toward partnering for late‑stage development. The company showcased Phase 1/1b results for WTX‑124, an IL‑2 INDUKINE, showing objective and durable responses as monotherapy in melanoma, cutaneous squamous cell carcinoma, and gastroesophageal junction cancer and in combination with pembrolizumab across multiple solid tumors as of October 30, 2025, with a 21% objective response rate in heavily pretreated advanced cutaneous melanoma and 30% in patients who had previously responded to immunotherapy; the FDA has accepted 18 mg as the recommended Phase 2 dose and provided initial guidance for a monotherapy registration path in post‑ICI relapsed or refractory melanoma. Werewolf also detailed early Phase 1b/2 data for its IL‑12 INDUKINE WTX‑330 through October 31 and December 2, 2025, indicating improved safety, favorable pharmacokinetics versus recombinant IL‑12 and antitumor activity including a confirmed partial response in metastatic gall bladder cancer, supported by an optimized manufacturing process. Looking ahead, the company expects to complete the WTX‑124 Phase 1/1b trial and deliver further data in the first half of 2026 and to provide an update from the dose‑finding Part A of the WTX‑330 Phase 1b/2 trial over the same period, but it signaled that additional funding and strategic partnerships will be required to advance both programs into registration‑enabling or combination studies, affecting the pace and scope of future clinical development. In parallel, Werewolf is advancing its INDUCER T‑cell engager platform, reporting preclinical data on WTX‑1011 and the newly announced WTX‑2022 that showed strong tumor‑specific activation, antitumor activity in xenograft models, and low cytokine release in non‑human primates, with cell line development and IND‑enabling studies underway and planned investigational filings around mid‑2027, subject to financing, positioning the company to compete as a differentiated player in next‑generation T‑cell engager therapies.

The most recent analyst rating on (HOWL) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Werewolf Therapeutics stock, see the HOWL Stock Forecast page.

Spark’s Take on HOWL Stock

According to Spark, TipRanks’ AI Analyst, HOWL is a Underperform.

Werewolf Therapeutics is facing significant financial and operational challenges, with ongoing losses and negative cash flows. The technical indicators suggest bearish momentum, and the valuation metrics reflect the company’s lack of profitability. These factors collectively contribute to a low overall stock score.

To see Spark’s full report on HOWL stock, click here.

More about Werewolf Therapeutics

Werewolf Therapeutics is a clinical-stage biotechnology company developing conditionally activated cancer immunotherapies built on its PREDATOR platform, which underpins two main modalities: INDUKINE cytokine prodrugs and INDUCER T‑cell engager molecules. Its pipeline includes IL‑2 and IL‑12 INDUKINE candidates WTX‑124 and WTX‑330 for advanced solid tumors, as well as emerging INDUCER T‑cell engagers WTX‑1011 targeting STEAP1 in prostate and other STEAP1‑positive cancers and WTX‑2022 targeting CDH6 in ovarian and other CDH6‑positive cancers, with an explicit focus on improving therapeutic index and tumor‑selective activity to address limitations of conventional immunotherapies.

Average Trading Volume: 948,693

Technical Sentiment Signal: Sell

Current Market Cap: $52.42M

For detailed information about HOWL stock, go to TipRanks’ Stock Analysis page.